Related Experiment Video

Updated: Sep 28, 2025

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.1K

Impact of COVID-19 on Management Strategies for Coronary and Structural Heart Disease Interventions

Lina Ya'Qoub1, Mohammad Alqarqaz1, Vaikom S Mahadevan2

  • 1Division of Interventional Cardiology, Henry Ford Hospital, Detroit, MI, USA.

Current Cardiology Reports
|March 29, 2022
PubMed

Insights

The COVID-19 pandemic challenged healthcare systems, impacting cardiac interventions and research. This review examines these effects and proposes solutions for structural heart disease and coronary syndromes.

Area of Science:

  • Cardiology
  • Public Health
  • Healthcare Management

Background:

  • The COVID-19 pandemic presented unprecedented global healthcare challenges.
  • Significant strain was placed on healthcare systems in the United States and worldwide.
  • Limited resources and system burden necessitated changes in patient care delivery.

Purpose of the Study:

  • To review the impact of COVID-19 on percutaneous coronary interventions and structural heart disease practices.
  • To assess the pandemic's effect on clinical research and trials in cardiology.
  • To discuss consensus recommendations and propose strategies to overcome challenges.

Main Methods:

  • Literature review of the impact of COVID-19 on cardiovascular interventions.
  • Analysis of changes in management for acute and chronic coronary syndromes.
  • Examination of pandemic effects on structural heart disease procedures and research.

Main Results:

  • The COVID-19 crisis significantly altered the management of patients with coronary syndromes and structural heart disease.
  • Practice evolved to prioritize high-risk patients and minimize exposure during procedures.
  • Pandemic conditions impacted the progression of related clinical research and trials.

Conclusions:

  • Healthcare systems adapted to provide essential cardiac care during the pandemic.
  • Strategies were developed to manage patients with complex cardiovascular conditions amidst resource limitations.
  • The review offers insights and recommendations for future preparedness in cardiovascular medicine.
Abstract

Keywords:
COVID-19Cardiac proceduresCardiovascular diseaseInterventional cardiologyPandemicStructural heart disease

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.8K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
42
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
47
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
39
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
60
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
26